Brain cancer hope: new drug combo shows promise in early trial

NCT ID NCT04959500

Ongoing Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the drug anlotinib hydrochloride to the standard Stupp regimen (chemoradiation) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 150 adults aged 18-75 with this aggressive brain tumor are participating. The trial is double-blind, meaning neither patients nor doctors know who gets the extra drug, to ensure fair results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anlotinib hydrochloride
What this could lead to: If successful, this could offer a new treatment option that slows the growth of glioblastoma, a fast-growing brain cancer.
What could go wrong: This is an early phase 2 trial with only 150 participants, so results may not apply to all patients. The drug also has side effects like high blood pressure and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Beijing TianTan Hospital,Capital Medical University

Beijing, Beijing Municipality, 100070, China
Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, 400000, China
Fudan University shabghai cancer center

Shanghai, Shanghai Municipality, 200433, China
Fujian Provincial Cancer Hospital

Fuzhou, Fujian, 350014, China
Gansu Provincial Hospital

Gansu, Lanzhou Province, 730000, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
Jiangxi Cancer Hospital

Nanchang, Jiangxi, 330029, China
Lanzhou University Second Hospital

Lanzhou, Gansu, 730000, China
Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, 110042, China
Shenzhen People's Hospital

Shenzhen, Guangdong, 518000, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The Fifth Affiliated Hospital Sun Yat-sen University

Zhuhai, Guangdong, 519000, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, 233004, China
The First Affiliated Hospital of NanChang University

Nanchang, Jiangxi, 330006, China
The First Hospital of Lanzhou University

Lanzhou, Gansu, 730000, China
The General Hospital of the People's Liberation Army (PLAGH)

Beijing, Beijing Municipality, 100853, China
The Second Affiliated Hospital of PLA Air Force Medical University

Xian, Shanxi, 710000, China
The Sixth Madical Center of PLA General Hospital

Beijing, Beijing Municipality, 100142, China
The affiliated hospital of xuzhou medical university

Xuzhou, Jiangsu, 221000, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
West China Hospital，Sichuan University

Chengdu, Sichuan, 610041, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.